AI Trading Robot Capitalizes on MACD Trend to Secure 4.47% Profit for $AMGN
Last week witnessed a strong performance from biotech firm Amgen (AMGN), with an artificial intelligence (AI)-based trading robot facilitating a 4.47% gain. This feat underlines the growing potential of AI in stock market trading. Specifically, the AI trading robot was able to leverage technical analysis, using the Moving Average Convergence Divergence (MACD) indicator, to exploit the inherent market opportunities.
For the uninitiated, the MACD is a trend-following momentum indicator that displays the relationship between two moving averages of a security's price. It involves subtracting the 26-period Exponential Moving Average (EMA) from the 12-period EMA. A nine-day EMA of the MACD, known as the "signal line," is then drawn on top of the MACD, which can function as a trigger for buy and sell signals.
In AMGN's case, the MACD turned positive on July 11, 2023, signaling a potential upward trend. This signal is considered bullish, indicating that it may be an optimal time to purchase shares. Historical analysis supports this: when AMGN's MACD turned positive in the past, the stock continued to rise in 27 out of 41 cases over the subsequent month, suggesting an upward trend continuation probability of 66%.
The AI trading robot capitalized on this signal, generating a profitable return of 4.47% over the course of the week. This was not a random outcome; rather, it demonstrates the efficacy of AI in discerning and acting upon complex market signals in real-time.
AI's success in this context lies in its ability to process vast amounts of data quickly and accurately, something that would take a human trader significantly more time. In addition to speed, AI can consistently apply trading rules without allowing emotions to interfere, a common pitfall for human traders.
In AMGN's case, the AI trading robot's strategy relied on the MACD's positive turn, an indicator that was substantiated by historical trends. It's a reminder that, while technical analysis cannot predict future price movements with 100% accuracy, it can provide valuable statistical insights into potential market behavior.
The AI trading robot's impressive 4.47% profit generation last week for AMGN illustrates the promising potential of AI in stock market trading. It serves as a testament to the potential synergy of technology and financial market, delivering significant returns based on reliable technical analysis tools like MACD. As the field of AI continues to evolve, we can expect an even greater precision and consistency in trading strategy execution, marking a new era of algorithmic trading.
AMGN in upward trend: 10-day moving average crossed above 50-day moving average on October 01, 2026
The 10-day moving average for AMGN crossed bullishly above the 50-day moving average on October 01, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 11 of 15 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 73%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where AMGN's RSI Oscillator exited the oversold zone, 18 of 27 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 67%.
The Momentum Indicator moved above the 0 level on September 22, 2026. You may want to consider a long position or call options on AMGN as a result. In 46 of 75 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 61%.
The Moving Average Convergence Divergence (MACD) for AMGN just turned positive on September 24, 2026. Looking at past instances where AMGN's MACD turned positive, the stock continued to rise in 31 of 48 cases over the following month. The odds of a continued upward trend are 65%.
Following a +2.18% 3-day Advance, the price is estimated to grow further. Considering data from situations where AMGN advanced for three days, in 191 of 311 cases, the price rose further within the following month. The odds of a continued upward trend are 61%.
AMGN may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 31 of 67 cases where AMGN's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 46%.
AMGN moved below its 50-day moving average on October 01, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where AMGN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 47%.
The Aroon Indicator for AMGN entered a downward trend on September 25, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 8 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (19.342) is normal, around the industry mean (19.199). P/E Ratio (25.971) is within average values for comparable stocks, (34.793). Projected Growth (PEG Ratio) (2.524) is also within normal values, averaging (5.738). Dividend Yield (0.024) settles around the average of (0.025) among similar stocks. P/S Ratio (5.371) is also within normal values, averaging (4.033).
The Tickeron Profit vs. Risk Rating rating for this company is 10 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 65, placing this stock better than average.
The Tickeron SMR rating for this company is 15 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 27 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 44 (best 1 - 100 worst), indicating steady price growth. AMGN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a manufacturer of human therapeutic products based on cellular biology
Industry PharmaceuticalsMajor
Advertisement